Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadekinig alfa randomized withdrawal trial in NLRC4 mutation and XIAP deficiency
2018-003297-27Phase 3Completed
- Sponsor
- AB2 Bio Ltd.
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in NLRC4-associated autoinflammatory disease (NLRC4-AID) and X-linked lymphoproliferative disease type 2 (XLP2) comparing Tadekinig alfa continuation with Placebo withdrawal (2 arms). Primary endpoint: Time to first disease reactivation during randomized withdrawal. Started Mar 2019; status: completed.
02
Drugs
tadekinig alfa
03
Conditions
NLRC4-associated autoinflammatory disease (NLRC4-AID)X-linked lymphoproliferative disease type 2 (XLP2)
Beyond the preview
Go deeper on 2018-003297-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003297-27.